| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 85,000 | NaN | ||
| Prepaid expenses | 0 | 14,018 | ||
| Cash on hand | NaN | 126 | ||
| Other current assets | 0 | NaN | ||
| Total current assets | 85,000 | 14,144 | ||
| Property and equipment, gross | 714,000 | NaN | ||
| Less accumulated depreciation | 25,000 | NaN | ||
| Cash and investments held in trust | NaN | 548,318 | ||
| Property and equipment, net | 689,000 | NaN | ||
| Total assets | 774,000 | 562,462 | ||
| Accounts payable | 4,288,000 | NaN | ||
| Promissory note - others | NaN | 1,398,107 | ||
| Accrued interest expense - others | NaN | 78,224 | ||
| Promissory note - related party-Related Party | NaN | 1,590,007 | ||
| Accrued interest expense - related party-Related Party | NaN | 110,237 | ||
| Accrued expenses | 1,266,000 | NaN | ||
| Accounts payable and accrued offering costs and expenses | NaN | 5,092,376 | ||
| Promissory notes | 4,478,000 | NaN | ||
| Total current liabilities | 10,032,000 | 8,268,951 | ||
| Deferred underwriter compensation | NaN | 2,887,500 | ||
| Related party loan | 5,335,000 | NaN | ||
| Total liabilities | 15,367,000 | 11,156,451 | ||
| Preferred stock, 0.0001 par value, 45,000,000 shares authorized as of september 30, 2025 and december 31, 2024 5,423,606 and no shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1,000 | NaN | ||
| Common stock, 0.0001 par value, 740,000,000 and 200,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 229,740,978 and 200,000,000 issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 23,000 | NaN | ||
| Additional paid-in capital | 255,025,000 | NaN | ||
| Accumulated deficit | -269,642,000 | -11,142,564 | ||
| Ordinary shares, value-Common Class B | NaN | 206 | ||
| Ordinary shares, value-Common Class A | NaN | 51 | ||
| Total stockholders' deficit | -14,593,000 | -11,142,307 | ||
| Class a ordinary shares subject to possible redemption 43,739 and 751,837 shares at redemption value of 12.54 and 12.00 per share as of june 30, 2025 and december 31, 2024, respectively | NaN | 548,318 | ||
| Total liabilities and stockholders' deficit | 774,000 | 562,462 | ||
Semnur Pharmaceuticals, Inc. (DNQAF)
Semnur Pharmaceuticals, Inc. (DNQAF)